Abstract: A method of deploying a neural network on a target device method includes extracting a number of device dependent error masks from the target device, using the number of device dependent error masks in a training phase of the neural network to generate a device dependent weight matrix for the neural network, and storing the device dependent weight matrix in the target device for use by the target device to perform inference tasks using the neural network.

Abstract: Various embodiments to mitigate the contamination of electroplated cobalt-platinum films on substrates are described. In one embodiment, a method of manufacture of a device includes depositing a diffusion barrier over a substrate, depositing a seed layer upon the diffusion barrier, and depositing a cobalt-platinum magnetic layer upon the seed layer. In a second embodiment, a method of manufacture of a device may include depositing a diffusion barrier over a substrate and depositing a cobalt-platinum magnetic layer upon the diffusion barrier. In a third embodiment, a method of manufacture of a device may include depositing an adhesion layer over a substrate, depositing a seed layer upon the adhesion layer, and depositing a cobalt-platinum magnetic layer over the seed layer. Based in part on these methods of manufacture, improvements in the interfaces between the layers can be achieved after annealing with substantial improvements in the magnetic properties of the cobalt-platinum magnetic layer.

Abstract: A method for forming a semiconductor device is provided. A first patterned mask is formed on the substrate, the first patterned mask having a first opening therein. A second patterned mask is formed on the substrate in the first opening, the first patterned mask and the second patterned mask forming a combined patterned mask. The combined patterned mask is formed having one or more second openings, wherein one or more unmasked portions of the substrate are exposed. Trenches that correspond to the one or more unmasked portions of the substrate are formed in the substrate in the one or more second openings.

Abstract: Systems and methods are disclosed that provide directional speakers and haptic devices for each guest of a ride vehicle. A controller may receive a vehicle location, seat location data, input audio data, and input haptic data. The seat location data may include a guest's seat location in the ride vehicle and/or the guest's preferences (e.g., a preferred language, volume preferences, or content rating preference). The controller may generate different audio output signals corresponding to different guests based on the input audio data, the vehicle location, and/or the seat location data, and generate different haptic output signals corresponding to different guests based on the input haptic data, the vehicle location, and/or the seat location data. The controller may then instruct directional speaker directed at the seat locations of the different guests to output the different audio output signals and instruct haptic devices directed at the seat locations to output the different haptic output signals.

Abstract: A travelling wave reactor for a space exploration. A reactor core of the travelling wave reactor is dispersed into several modules in a travelling wave direction; a new reactor is sequentially provided with a starting source module and a plurality of new fuel modules at zero burnup; all the modules are coaxially assembled in the travelling wave direction by means of an assembling parts, and each module further includes a heat pipe; the heat pipe in each module positioned at a front part sequentially passes through all the modules positioned at a rear portion thereof and extends out of the module at a rear end; and after a period of time of burn-up, the reactor core of the travelling wave reactor is provided with the starting source module, a spent fuel module, a critical fuel module and the new fuel module sequentially in the travelling wave direction.

Abstract: The disclosure is directed in non-limiting embodiments to compounds, compositions, and methods of treating conditions and diseases associated with activation of the gonadotropin GnRH receptor (GnRHR), particularly those involving GnRHR activating autoantibodies (GnRHR AAbs). In one non-limiting embodiment, the disease is Polycystic Ovary Syndrome (PCOS). The therapeutic compounds in at least certain embodiments include peptides which at least partially comprise D-amino acids, such as retro-inverso D-amino acid (RID) peptides, which are able to bind with high affinity to GnRHR AAbs.

Abstract: An exemplary multi-robot system can include, for example, a first robot(s), which can include a communication arrangement and a sensor arrangement configured to detect a presence of an object(s) within a predetermined distance from the first robot(s), and determine a distance from the first robot(s) to the object(s), where the first robot(s) can broadcast a query to the object(s) using the communication arrangement, identify the object(s) as a second robot(s) or a non-robot based on a response received from the object(s). The sensor arrangement can be a Light Detection and Ranging (LiDAR) sensor arrangement. The LiDAR sensor arrangement can be a two-dimensional LiDAR sensor arrangement.

Abstract: The present disclosure provides, among other things, methods for colorectal cancer, breast cancer, lung cancer and/or pancreatic cancer detection (e.g., screening) and compositions related thereto. In various embodiments, the present disclosure provides methods for screening that include analysis of methylation status of one or more methylation biomarkers, and compositions related thereto. In various embodiments, the present disclosure provides methods for detection (e.g., screening) that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA. In various embodiments, the present disclosure provides methods for screening that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA, using MSRE-qPCR and/or using massively parallel sequencing (e.g., next-generation sequencing).

Abstract: According to exemplary embodiments of the present disclosure, it is possible to provide method, system, arrangement, computer-accessible medium and device to stimulate individual neurons in brain slices in any arbitrary spatio-temporal pattern, using two-photon uncaging of photo-sensitive compounds such as MNI-glutamate and/or RuBi-Glutamate with beam multiplexing. Such exemplary method and device can have single-cell and three-dimensional precision. For example, by sequentially stimulating up to a thousand potential presynaptic neurons, it is possible to generate detailed functional maps of inputs to a cell. In addition, it is possible to combine this exemplary approach with two-photon calcium imaging in an all-optical method to image and manipulate circuit activity. Further exemplary embodiments of the present disclosure can include a light-weight, compact portable device providing for uses in a wide variety of applications.

Abstract: The present disclosure provides methods and compositions for the treatment, identification, diagnosis, and prognosis of dystonia, or dystonia related disorders.

Abstract: Mussels strongly adhere to a variety of surfaces by secreting byssal threads that contain mussel foot proteins (Mfps). Recombinant production of Mfps presents an attractive route for preparing advanced adhesive materials. Using synthetic biology strategies, Mfp5 together with Mfp5 oligomers containing two or three consecutive, covalently-linked Mfp5 sequences (named Mfp52 and Mfp53) were synthesized. Positive correlations were found between Mfp5 molecular weight and underwater adhesive properties, including adhesion force, adhesion work, protein layer thickness, and recovery distance. Dopa-modified Mfp53 displayed a high adhesion force (201±36 nN ?m?1) and a high adhesion work (68±21 fJ ?m?1) for 200 s cure times, higher than previously reported Mfp-mimetic adhesives. Results disclosed herein highlight the power of synthetic biology in producing biocompatible and highly adhesive Mfp-based materials.

Abstract: The present invention discloses a novel double-valve continuous circulating valve with a clamping device, comprising a main through valve (5), a pup joint body (8), a middle connector (11) and a bypass valve (12); the main through valve seat (4), the main through valve (5) and the main through valve spring (6) are press-fitted in the pup joint body (8) through a main through valve limiting device (1); a bypass valve seat (10) is arranged at the lower side of the pup joint body (8), and the bypass valve (12) is mounted and fixed to the bypass valve seat (10) through a bypass valve limiting device (9); the middle connector (11) is press-fitted on the pup joint body (8) through a clamping device. The present invention solves the technical problems of dangerous incidents caused by the suspension of circulating medium.

Abstract: A method may include receiving a consent-processing request at a consent management platform from a content-presentation device, and using an identifier string in the request to establish a secure interactive session configured for user selection of consent options associated with a particular consent package of the platform, where the package may include identifiers of consent features of a media distribution system that require user consent in order to be activated for the device. The platform may then receive, via the interactive session, user consent data including a respective consent choice for each of one or more consent options, where each respective consent choice indicates acceptance or rejection of consent to activating an associated consent feature identified with the particular consent package. The received respective consent choices may be stored in a database of the consent management platform. Corresponding data may be stored in a whitelist on the content-presentation device.

Abstract: The present invention relates to methods for determining endonuclease activity in a sample. In particular, the present invention relates to a method for determining viable pathogenic bacteria in a sample based on patterns of endonuclease activity.

Abstract: The present disclosure includes refactored thaxtomin biosynthetic gene clusters including thaxtomin modules including one or more thaxtomin genes such that the expression of the refactored thaxtomin biosynthetic gene cluster produces at least one thaxtomin compound in the absence of thaxtomin-inducing conditions. Also included are genetically engineered Streptomyces bacterium from a non-pathogenic Streptomyces strain comprising an exogenous, refactored thaxtomin biosynthetic gene cluster of the present disclosure, such that the expression of the refactored thaxtomin biosynthetic gene cluster provides the genetically engineered Streptomyces bacterium with the ability to produce at least one thaxtomin compound in the absence of thaxtomin-inducing conditions. The present disclosure also includes methods of producing thaxtomin compounds, analogs, or intermediate with the refactored thaxtomin biosynthetic gene clusters and genetically engineered bacteria of the present disclosure.

Abstract: Disclosed herein are nanoparticles comprising a lipid core comprising a sterol; and a complex comprising a cationic agent and a therapeutic agent, wherein the complex is encapsulated within the lipid core. Methods to produce the nanoparticle comprise: combining a cationic agent, a therapeutic agent, and a first water-immiscible solvent with a first aqueous solution, thereby forming a mixture comprising a complex comprising the cationic agent and the therapeutic agent; combining the mixture with a second waterim-miscible solvent, thereby forming an aqueous phase and an organic phase, and separating the organic phase comprising the complex; combining the organic phase comprising the complex with a sterol and a first water-miscible organic solvent; and dispersing the complex in a second aqueous solution to form a herein disclosed nanoparticle. Methods for treating a disease and for reducing nanoparticle burst rate are also disclosed.

Abstract: Disclosed are methods of treating a disorder or disease associated with myotonic dystrophy. Methods of treating a CNS dysfunction and/or cognitive impairment associated with myotonic dystrophy in a subject comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed. Methods of treating a myotonic dystrophy associated disease or disorder caused by mis-splicing of GABRG2 in a subject comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed. Methods of improving cognitive function or alertness in a subject having myotonic dystrophy comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed.

Abstract: Disclosed herein are various medical device components, including components that can be incorporated into robotic and/or in vivo medical devices. Also disclosed are various medical devices for in vivo medical procedures. Included herein, for example, is a surgical robotic device having an elongate device body, a right robotic arm coupled to a right shoulder assembly, and a left robotic arm coupled to a left shoulder assembly.

Abstract: Preparation, characterization, and an electrochemical study of Mg0.1V2O5 prepared by a novel sol-gel method with no high-temperature post-processing are disclosed. Cyclic voltammetry showed the material to be quasi-reversible, with improved kinetics in an acetonitrile-, relative to a carbonate-, based electrolyte. Galvanostatic test data under a C/10 discharge showed a delivered capacity >250 mAh/g over several cycles. Based on these results, a magnesium anode battery, as disclosed, would yield an average operating voltage ˜3.2 Volts with an energy density ˜800 mWh/g for the cathode material, making the newly synthesized material a viable cathode material for secondary magnesium batteries.

Abstract: Methods are disclosed herein for producing human hepatocytes from human induced pluripotent stem cells. Also provided are transgenic rats for the expansion of human hepatocytes, such as those produced using the methods disclosed herein.